Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms

References

• Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31 (7):844–860. doi:10.1016/j.annonc.2020.03.304.
   PubMed Web of Science ®Google Scholar
• Klimstra D, Klöppel G, La Rosa S, et al. WHO Classification of Tumors Editorial Board Digestive System Tumors, WHO Classification of Tumors. Lyon: International Agency for Research on Cancer Press; 2019.
   Google Scholar
• Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017; 3 (10):1335–1342. doi:10.1001/jamaoncol.2017.0589.
   PubMed Web of Science ®Google Scholar
• Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G, et al. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017; 58 (2):368–379. doi:10.1007/s12020-017-1273-x.
   PubMed Web of Science ®Google Scholar
• Amarnath S, Mangus CW, Wang JCM, Wei F, He A, Kapoor V, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med. 2011; 3 (111):111ra120. doi:10.1126/scitranslmed.3003130.
   PubMed Web of Science ®Google Scholar
• Dudley JC, Lin M-T, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016; 22 (4):813–820. doi:10.1158/1078-0432.CCR-15-1678.
   PubMed Web of Science ®Google Scholar
• Andrews LP, Marciscano AE, Drake CG, Vignali DAA. LAG 3 (CD 223) as a cancer immunotherapy target. Immunol Rev. 2017; 276 (1):80–96. doi:10.1111/imr.12519.
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010; 207 (10):2175–2186. doi:10.1084/jem.20100637.
   PubMed Web of Science ®Google Scholar
• Higgins LM, McDonald SA, Whittle N, Crockett N, Shields JG, MacDonald TT, et al. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol. 1999; 162 (1):486–493. doi:10.4049/jimmunol.162.1.486.
   PubMed Web of Science ®Google Scholar
• Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, et al. Pembrolizumab for the treatment of programmed death–ligand 1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study. Cancer. 2020; 126 (13):3021–3030. doi:10.1002/cncr.32883.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020; 38 (1):1–10. doi:10.1200/JCO.19.02105.
   PubMed Web of Science ®Google Scholar
• Vijayvergia N, Dasari A, Deng M, Litwin S, Al-Toubah T, Alpaugh RK, et al. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. Br J Cancer. 2020; 122 (9):1309–1314. doi:10.1038/s41416-020-0775-0.
   PubMed Web of Science ®Google Scholar
• Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, et al. Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). Ann Oncol. 2018; 29:viii467–viii468. doi:10.1093/annonc/mdy293.001.
   Web of Science ®Google Scholar
• Lu M, Zhang P, Zhang Y, Li Z, Gong J, Li J, et al. Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib TrialToripalimab in Recurrent or Metastatic NENs. Clin Cancer Res. 2020; 26 (10):2337–2345. doi:10.1158/1078-0432.CCR-19-4000.
   PubMed Web of Science ®Google Scholar
• Fottner C, Apostolidis L, Ferrata M, et al. A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC). J Clin Oncol. 2019;37:4103–4103. doi:10.1200/JCO.2019.37.15_suppl.4103.
   Google Scholar
• Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, et al. A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumorsıpilimumab and nivolumab in rare tumors S1609: Neuroendocrine. Clin Cancer Res. 2020; 26 (10):2290–2296. doi:10.1158/1078-0432.CCR-19-3356.
   PubMed Web of Science ®Google Scholar
• Capdevila J, Teule A, López C, García-Carbonero R, Benavent M, Custodio A, et al. 1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). Annals of Oncology. 2020; 31:S770–S771. doi:10.1016/j.annonc.2020.08.1370.
   Web of Science ®Google Scholar
• Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022; 386 (1):24–34. doi:10.1056/NEJMoa2109970.
   PubMed Web of Science ®Google Scholar
• Kim ST, Ha SY, Lee S, Ahn S, Lee J, Park SH, et al. The impact of PD-L1 expression in patients with metastatic GEP-NETs. J Cancer. 2016; 7 (5):484–489. doi:10.7150/jca.13711.
   PubMed Web of Science ®Google Scholar
• Bösch F, Brüwer K, Altendorf-Hofmann A, Auernhammer CJ, Spitzweg C, Westphalen CB, et al. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia. Endocr Relat Cancer. 2019; 26 (3):293–301. doi:10.1530/ERC-18-0494.
   PubMed Web of Science ®Google Scholar
• Cavalcanti E, Armentano R, Valentini AM, Chieppa M, Caruso ML. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis. 2017; 8 (8):e3004-e3004–e3004. doi:10.1038/cddis.2017.401.
   Google Scholar
• Oktay E, Yalcin GD, Ekmekci S, et al. Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors. Jbuon. 2019; 24 (2):779–790.
   Google Scholar
• Strosberg J, Mizuno N, Doi T, Grande E, Delord J-P, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 studypembrolizumab monotherapy for advanced neuroendocrine tumors. Clin Cancer Res. 2020; 26 (9):2124–2130. doi:10.1158/1078-0432.CCR-19-3014.
   PubMed Web of Science ®Google Scholar
• Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol. 2011; 186 (9):5173–5183. doi:10.4049/jimmunol.1002050.
   PubMed Web of Science ®Google Scholar
• Huang R-Y, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K, et al. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015; 6 (29):27359–27377. doi:10.18632/oncotarget.4751.
   PubMedGoogle Scholar
• Wierz M, Pierson S, Guyonnet L, Viry E, Lequeux A, Oudin A, et al. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood, The Journal of the American Society of Hematology. 2018; 131 (14):1617–1621. doi:10.1182/blood-2017-06-792267.
   Google Scholar
• Schöffski P, Tan DSW, Martín M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, et al. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525)±anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022; 10 (2):e003776. doi:10.1136/jitc-2021-003776.
   PubMed Web of Science ®Google Scholar
• Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Semin Immunol. 2019;42:101305. Elsevier; doi:10.1016/j.smim.2019.101305.
   PubMed Web of Science ®Google Scholar
• He Y, Zhang X, Jia K, Dziadziuszko R, Zhao S, Deng J, et al. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Transl Lung Cancer Res. 2019; 8 (4):352–366. doi:10.21037/tlcr.2019.08.15.
   PubMed Web of Science ®Google Scholar
• Jiang J, Jin M-S, Kong F, Cao D, Ma H-X, Jia Z, et al. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLoS One. 2013; 8 (12):e81799. doi:10.1371/journal.pone.0081799.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Komrokji RS, Brunner AM. TIM-3 pathway dysregulation and targeting in cancer. Expert Rev Anticancer Ther. 2021; 21 (5):523–534. doi:10.1080/14737140.2021.1865814.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010; 207 (10):2187–2194. doi:10.1084/jem.20100643.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Gelderblom H, Mach N, Doi T, Tai WMD, Forde P, et al. Abstract CT183: Phase (Ph) I/II study of MBG453 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies. Cancer Research. 2019; 79 (13_Supplement):CT183–CT183. doi:10.1158/1538-7445.AM2019-CT183.
   Google Scholar
• Curigliano G, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, et al. Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors. Clin Cancer Res. 2021; 27 (13):3620–3629. doi:10.1158/1078-0432.CCR-20-4746.
   PubMed Web of Science ®Google Scholar
• Sapski S, Beha N, Kontermann R, Müller D. Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors. Oncoimmunology. 2017; 6 (12):e1361594. doi:10.1080/2162402X.2017.1361594.
   PubMed Web of Science ®Google Scholar
• Hebb JPO, Mosley AR, Vences-Catalán F, Rajasekaran N, Rosén A, Ellmark P, et al. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. Cancer Immunol Immunother. 2018; 67 (1):47–60. doi:10.1007/s00262-017-2059-y.
   PubMed Web of Science ®Google Scholar
• Paul S, Kulkarni N, Lal G. Shilpi Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells. Oncoimmunology. 2016; 5 (12):e1235106. doi:10.1080/2162402X.2016.1235106.
   PubMed Web of Science ®Google Scholar
• Ladányi A, Somlai B, Gilde K, Fejös Z, Gaudi I, Tímár J, et al. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res. 2004; 10 (2):521–530. doi:10.1158/1078-0432.ccr-1161-03.
   PubMed Web of Science ®Google Scholar
• Chen P, Wang H, Zhao L, Guo H, Zhang L, Zhang W, et al. Immune checkpoints OX40 and OX40L in small-cell lung cancer: predict prognosis and modulate ımmune microenvironment. Front Oncol. 2021; 11:713853. doi:10.3389/fonc.2021.713853.
   PubMed Web of Science ®Google Scholar
• Chen X, Ma H, Mo S, Zhang Y, Lu Z, Yu S, et al. Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma. Front Immunol. 2022;13:942154. doi:10.3389/fimmu.2022.942154.
   PubMed Web of Science ®Google Scholar
• Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019; 12 (1):54. doi:10.1186/s13045-019-0738-1.
   PubMed Web of Science ®Google Scholar
• Cicek MS, Lindor NM, Gallinger S, Bapat B, Hopper JL, Jenkins MA, et al. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population-And clinic-based colorectal tumors: results from the colon cancer family registry. J Mol Diagn. 2011; 13 (3):271–281. doi:10.1016/j.jmoldx.2010.12.004.
   PubMed Web of Science ®Google Scholar
• House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Cameron JL, et al. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. Surgery. 2003; 134 (6):902–908; discussion 909. doi:10.1016/s0039-6060(03)00412-4.
   PubMed Web of Science ®Google Scholar
• Sahnane N, Furlan D, Monti M, Romualdi C, Vanoli A, Vicari E, et al. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer. 2015; 22 (1):35–45. doi:10.1530/ERC-14-0410.
   PubMed Web of Science ®Google Scholar
• Boer FL, Ten Eikelder MLG, Kapiteijn EH, Creutzberg CL, Galaal K, van Poelgeest MIE, et al. Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature. Cancer Treat Rev. 2019; 73:91–103. doi:10.1016/j.ctrv.2018.12.005.
   PubMed Web of Science ®Google Scholar
• Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM, et al. Microsatellite instability and gene mutations in transforming growth factor‐beta type II receptor are absent in small bowel carcinoid tumors. Cancer. 2005; 103 (2):229–236. doi:10.1002/cncr.20750.
   PubMed Web of Science ®Google Scholar
• Arnold CN, Sosnowski A, Schmitt-Gräff A, Arnold R, Blum HE. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro‐entero‐pancreatic system. Int J Cancer. 2007; 120 (10):2157–2164. doi:10.1002/ijc.22569.
   PubMed Web of Science ®Google Scholar
• Xing J, Ying H, Li J, Gao Y, Sun Z, Li J, et al. Immune checkpoint markers in neuroendocrine carcinoma of the digestive system. Front Oncol. 2020; 10:132. doi:10.3389/fonc.2020.00132.
   PubMed Web of Science ®Google Scholar
• Arnason T, Sapp HL, Rayson D, Barnes PJ, Drewniak M, Nassar BA, et al. Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors. Arch Pathol Lab Med. 2011; 135 (12):1539–1544. doi:10.5858/arpa.2010-0560-OA.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372 (26):2509–2520. doi:10.1056/NEJMoa1500596.
   PubMed Web of Science ®Google Scholar
• Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid TumorsFDA Approval Summary: Pembrolizumab for MSI-H Solid Tumors. Clin Cancer Res. 2019;25(13):3753–3758. doi:10.1158/1078-0432.CCR-18-4070.
   PubMed Web of Science ®Google Scholar